Search

everythinglearnresearchcommunity

for

Search:↓

Deuruxolitinib improves anxiety and depression in severe alopecia areata patients.

Potassium channel activators like nicotinamide and minoxidil might help treat solid tumors.

Breast cancer patients taking CDK4/6 inhibitors are more likely to experience fatigue, hair loss, and mouth sores.

JAK inhibitors show promise for treating skin diseases effectively and safely.

Topical Ruxolitinib may safely treat severe hair loss.

Applying 2% tofacitinib cream helped some children with severe hair loss grow back hair.

Baricitinib quickly improved severe alopecia areata, with almost total hair regrowth in three months.

Ritlecitinib provides new treatment options for diverse alopecia areata patients.

Oral tofacitinib may be an effective and tolerable treatment for some people with severe alopecia areata.

Targeted cancer therapies often cause skin reactions, so dermatologists must manage these effects.

Combining irinotecan and cetuximab is effective for some metastatic colorectal cancer patients but often causes manageable skin issues.

Ruxolitinib treatment may cause eyelash growth.

DMBT1 and galectin-3 may help suppress epithelial skin cancer.

Sonidegib often causes hair loss, and LC-OCT helps identify early signs.

Baricitinib significantly regrows hair in severe alopecia areata patients.

Ritlecitinib is the first FDA-approved pill for treating significant hair loss in alopecia areata patients aged 12 and up.

Doxycycline helps prevent skin issues from erlotinib in lung cancer patients.

JAK inhibitors like tofacitinib are effective and safer for severe alopecia areata than glucocorticosteroids.

Kanglaite injection with chemotherapy improves treatment and reduces side effects for advanced lung cancer.

A JAK1 variant causes hair loss, skin issues, and thyroid disease, but treatment with a specific inhibitor can help.

Linoleic acid and magnesium are key in alopecia areata progression, and tofacitinib can help by affecting their pathway.

Baricitinib can cause excessive hair growth.

Tofacitinib and low-dose IL-2 may help maintain hair regrowth in alopecia areata without ongoing treatment.

Antizyme slows skin tumor growth by reducing cell growth in mice.

The committee decided not to approve the drug due to low effectiveness and high risks.

Continued ritlecitinib treatment helps sustain hair regrowth in alopecia areata patients.

The FDA approved Litfulo® for treating severe alopecia areata in people aged 12 and older.